49 Spam-Free Article(s) Found
Article Searches
CytoDyn's Leronlimab Progressing Well in Coronavirus Program http://www.zacks.com/stock/news/874193/cytodyns-leronlimab-progressing-well-in-coronavirus-program?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-874193 Apr 16, 2020 - CytoDyn (CYDY) treats first patient in a phase IIb/III study evaluating leronlimab in severe and critically ill COVID-19 patients. A phase II study on leronlimab shows encouraging results in mild-to-moderate COVID-19 patients.
AstraZeneca to Begin Calquence Study for Coronavirus Treatment http://www.zacks.com/stock/news/872061/astrazeneca-to-begin-calquence-study-for-coronavirus-treatment?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-872061 Apr 15, 2020 - AstraZeneca (AZN) to initiate enrollment in a clinical study to evaluate its blood cancer drug, Calquence, as a potential treatment for patients hospitalized with COVID-19 infection.
Buy 5 Top Stocks Set to Beat on Q1 Earnings This Month http://www.zacks.com/stock/news/871880/buy-5-top-stocks-set-to-beat-on-q1-earnings-this-month?cid=CS-ZC-FT-analyst_blog|investment_ideas-871880 Apr 15, 2020 - Despite the economic disaster, a few stocks are likely to report better-than expected earnings results when they report their financial numbers this month.
SNY vs. LLY: Which Stock Is the Better Value Option? http://www.zacks.com/stock/news/870517/sny-vs-lly-which-stock-is-the-better-value-option?cid=CS-ZC-FT-tale_of_the_tape|yseop_template_3-870517 Apr 14, 2020 - SNY vs. LLY: Which Stock Is the Better Value Option?
Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo http://www.zacks.com/stock/news/868599/zackscom-featured-highlights-include-electromed-novagold-resources-fti-consulting-eli-lilly-and-masimo?cid=CS-ZC-FT-press_releases-868599 Apr 13, 2020 - Zacks.com featured highlights include: Electromed, NovaGold Resources, FTI Consulting, Eli Lilly and Masimo
Lilly Announces Clinical Study Plans for Coronavirus Disease http://www.zacks.com/stock/news/868591/lilly-announces-clinical-study-plans-for-coronavirus-disease?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-868591 Apr 13, 2020 - Lilly (LLY) plans to develop its RA drug, Olumiant, as well as a pipeline candidate as potential treatments for COVID-19. Clinical studies are expected to begin this month.
Eli Lilly Starts Clinical Trial for Potential COVID-19 Treatment https://www.fool.com/investing/2020/04/11/eli-lilly-starts-clinical-trial-for-potential-covi.aspx?source=iedfolrf0000001 Apr 11, 2020 - The pharma company believes that its rheumatoid arthritis treatment Olumiant could be effective at treating COVID-19 patients.
Pfizer's Braftovi Combo Gets FDA Nod for Colorectal Cancer http://www.zacks.com/stock/news/863161/pfizers-braftovi-combo-gets-fda-nod-for-colorectal-cancer?cid=CS-ZC-FT-analyst_blog|company_news_-_medical_sector-863161 Apr 09, 2020 - Pfizer (PFE) secures an FDA approval for Braftovi combined with Lilly's Erbitux to treat BRAFV600E-mutant metastatic colorectal cancer in patients who received prior therapy.
5 Stocks With Recent Price Strength Amid Coronavirus Logjam http://www.zacks.com/stock/news/862418/5-stocks-with-recent-price-strength-amid-coronavirus-logjam?cid=CS-ZC-FT-analyst_blog|rw-862418 Apr 09, 2020 - Investors target stocks that are witnessing a bullish run. Actually, stocks seeing price strength have a high chance of carrying the momentum forward.
5 Low-Risk Stocks to Buy for Epic Price Swings Since 1929 http://www.zacks.com/stock/news/860620/5-low-risk-stocks-to-buy-for-epic-price-swings-since-1929?cid=CS-ZC-FT-analyst_blog|investment_ideas-860620 Apr 08, 2020 - The S&P 500's average daily percentage price change over the past five weeks has been plus or minus 4.8%. This explains why the Cboe Volatility Index remains elevated at around the 40s.

Pages: 12345

<<<Page 3>